| pubmed-article:8070324 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0025932 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0226896 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0205531 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C1527415 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0040845 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0281666 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C1705241 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:8070324 | lifeskim:mentions | umls-concept:C1705242 | lld:lifeskim |
| pubmed-article:8070324 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8070324 | pubmed:dateCreated | 1994-9-28 | lld:pubmed |
| pubmed-article:8070324 | pubmed:abstractText | All trans-retinoic acid (tr-RA) has been used to induce leukemic cell differentiation in patients with acute promyelocytic leukemia (APL). However, the duration of remission is brief and is associated with a progressive decrease in peak plasma concentrations following chronic dosing. 9-Cis-retinoic acid (9-cis-RA) has the potential to elicit the same effects as tr-RA, because it can bind and activate the same family of nuclear receptors. It is not known whether the pharmacokinetics of this novel compound resemble those of tr-RA. In this study, we report major differences in the uptake and pharmacokinetics between orally administered tr-RA and 9-cis-RA in the plasma of nude mice. Following a single initial oral administration of either isomer, the plasma peak time of 9-cis-RA (15-30 min) occurred earlier than that of tr-RA (60-180 min), but with lower plasma concentrations and area under the concentration-time curve (AUC) value. A decrease in the AUC of plasma tr-RA was seen in animals that were given a second dose 2 days after the first dose. In contrast, an increase in the AUC of plasma 9-cis-RA was seen in animals that were given a second dose 2 days after the first dose. This increase was due to the appearance of a second 9-cis-RA peak at 180 min. When liarozole, an inhibitor of tr-RA metabolism, was coadministered with the initial tr-RA dose or a second tr-RA dose 2 weeks later, the AUC of plasma tr-RA was increased relative to tr-RA alone.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:8070324 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8070324 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8070324 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8070324 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8070324 | pubmed:issn | 0090-9556 | lld:pubmed |
| pubmed-article:8070324 | pubmed:author | pubmed-author:GudasL JLJ | lld:pubmed |
| pubmed-article:8070324 | pubmed:author | pubmed-author:MillerW HWHJr | lld:pubmed |
| pubmed-article:8070324 | pubmed:author | pubmed-author:ScherH IHI | lld:pubmed |
| pubmed-article:8070324 | pubmed:author | pubmed-author:BoylanJ FJF | lld:pubmed |
| pubmed-article:8070324 | pubmed:author | pubmed-author:BentelJ MJM | lld:pubmed |
| pubmed-article:8070324 | pubmed:author | pubmed-author:AchkarC CCC | lld:pubmed |
| pubmed-article:8070324 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8070324 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:8070324 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8070324 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8070324 | pubmed:pagination | 451-8 | lld:pubmed |
| pubmed-article:8070324 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:meshHeading | pubmed-meshheading:8070324-... | lld:pubmed |
| pubmed-article:8070324 | pubmed:articleTitle | Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. | lld:pubmed |
| pubmed-article:8070324 | pubmed:affiliation | Department of Pharmacology, Cornell University Medical College, New York, NY 10021. | lld:pubmed |
| pubmed-article:8070324 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8070324 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8070324 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8070324 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8070324 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8070324 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8070324 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8070324 | lld:pubmed |
